VEGFA (NM_001025366) Human Recombinant Protein

CAT#: TP780001

Recombinant protein of human Vascular endothelial growth factor A (VEGF) produced in Pichia Pastoris.

Bulk Request/Custom Protein Development


 Product Datasheet for 'TP780001'

USD 399.00


Availability*
In Stock

Size
    • 50 ug

Product images

Specifications

Product Data
Description Recombinant protein of human Vascular endothelial growth factor A (VEGF) produced in Pichia Pastoris.
Species Human
Expression Host Pichia
Expression cDNA Clone or AA Sequence A DNA sequence from TrueORF clone, RC229662. Encoding the region (Ala27-Arg191) of human VEGFA
Tag Tag Free
Predicted MW 19.2 kDa
Concentration Resuspend the protein to the desired concentration in proper buffer.
Purity >95% as determined by SDS-PAGE and Coomassie blue staining
Buffer Lyophilized from a sterile solution containing 20 mM phosphate buffer, pH7.2
Bioactivity Measured in a cell proliferation assay using HUVEC Cells. The ED50 for this effect is typically 1.1 - 1.6 ng/ml.
Endotoxin <0.1 EU per 1 µg of the protein by the LAL
Reference Data
RefSeq NP_001020537
Locus ID 7422
Refseq Size 3665
Cytogenetics 6p21.1
Refseq ORF 1236
Synonyms MVCD1; VEGF; VPF
Summary This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015].
Protein Families
Protein Pathways
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents